Eric A Dietrich, Pharm.D., BCACP, CPC-A, CEMC, CPB
Clinical Associate Professor
Department:
Pharmacy Education and Practice
Business Phone:
(352) 294-5648
Business Email:
dietrich@cop.ufl.edu
About Eric A Dietrich
Dr. Dietrich is a Clinical Associate Professor within the Department of Pharmacy Education and Practice. His work involves managing an Anticoagulation Clinic at UF Health Internal Medicine at Kanapaha monitoring warfarin as well as DOACs in addition to a multidisciplinary transitions of care clinic for patients with a recent acute myocardial infarction housed within UF Health Shands Cardiology service. Dr. Dietrich’s research interests include interventions aimed at reducing anticoagulation, hypertension, cardiovascular disease, and pharmacy billing and reimbursement for clinical services in collaborative clinical environments. Dr. Dietrich is a Board Certified Ambulatory Care Pharmacist as well as a Certified Professional Coder. Dr. Dietrich’s teaching focuses on anticoagulation, cardiovascular disease, osteoporosis, pharmacy billing, and Ambulatory Care. He has two children who keep him busy and full of joy and gratitude.
Accomplishments
Member
2016-current
·
American Academy of Profession Coders
Member
2011-current
·
American College of Clinical Pharmacy
Teaching Profile
Courses Taught
2018,2020-2023
PHA5878C Pt Care 3: Cv and Pulm
2018-2024
PHA5876C Pt Care 8 Complex Pts
2018-2019,2021-2022
PHA5789C Patient Care 7
2018
PHA5788C Patient Care 6
2018
PHA5763 Ambulatory Care Advanced Pharmacy Practice Experience
2018,2020-2023
PHA5060 Ambulatory Care
2012-2018
PHA5788 Pharmacotherapy 6
2016-2017
PHA5787 Pharmacotherapy 5
2014-2016
PHA5784 Pharmacotherapy 4
2015-2016
PHA5933 Select Top Pharmacy
2015
PHA6634 Medication Therapy Management: An Endocrine Focus
2015
PHA5907 Research in Phar Prac
2012-2015
PHA5783 Pharmacotherapy 3
2011
PHA5782 Pharmacotherapy 2
2021
PHA5519 Advanced Topics in Anticoagulation Pharmacotherapy
2024
PHA5787C Pt Care 5: Endo
Clinical Profile
Specialties
- Pharmacy
Research Profile
Areas of Interest
- Anticoagulation; DOAC monitoring
- Collaborative Practice Models
- Hypertension
- Pharmacy Billing and Reimbursement
Publications
2024
Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
81(14):599-607
[DOI] 10.1093/ajhp/zxae053.
[PMID] 38427969.
2024
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
24(3):455-464
[DOI] 10.1007/s40256-024-00648-2.
[PMID] 38691312.
2023
Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism.
Clinical and translational science.
16(6):946-954
[DOI] 10.1111/cts.13510.
[PMID] 36891985.
2023
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
Clinical and translational science.
16(1):128-139
[DOI] 10.1111/cts.13433.
[PMID] 36200137.
2023
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Pharmacotherapy.
43(10):1024-1031
[DOI] 10.1002/phar.2853.
[PMID] 37459069.
2023
Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.
Journal of managed care & specialty pharmacy.
29(11):1219-1230
[DOI] 10.18553/jmcp.2023.29.11.1219.
[PMID] 37889866.
2023
Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding.
Research and practice in thrombosis and haemostasis.
7(3)
[DOI] 10.1016/j.rpth.2023.100131.
[PMID] 37159747.
2023
Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
The Annals of pharmacotherapy.
57(12):1349-1360
[DOI] 10.1177/10600280231155489.
[PMID] 36999519.
2023
Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction.
American heart journal plus : cardiology research and practice.
26
[DOI] 10.1016/j.ahjo.2023.100259.
[PMID] 38510191.
2022
Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.
Journal of internal medicine.
291(6):877-885
[DOI] 10.1111/joim.13462.
[PMID] 35192737.
2022
Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
Clinical pharmacology and therapeutics.
112(1):133-145
[DOI] 10.1002/cpt.2611.
[PMID] 35420702.
2022
Impact of an ambulatory care pharmacist on provider relative value units in a rural clinic.
Exploratory research in clinical and social pharmacy.
5
[DOI] 10.1016/j.rcsop.2021.100098.
[PMID] 35478518.
2022
Semaglutide for Weight Loss.
The Annals of pharmacotherapy.
56(2):224-226
[DOI] 10.1177/10600280211027204.
[PMID] 34157885.
2022
Simplifying medical decision-making for clinical pharmacists.
Research in social & administrative pharmacy : RSAP.
18(6):3072-3075
[DOI] 10.1016/j.sapharm.2021.07.026.
[PMID] 34384715.
2021
Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis.
American heart journal.
242:71-81
[DOI] 10.1016/j.ahj.2021.08.014.
[PMID] 34450051.
2021
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Annals of internal medicine.
174(7):910-919
[DOI] 10.7326/M20-6194.
[PMID] 33780291.
2021
Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
Pharmacotherapy.
41(9):710-721
[DOI] 10.1002/phar.2610.
[PMID] 34170559.
2020
Ambulatory care elective: Introduction to core practice concepts.
Currents in pharmacy teaching & learning.
12(3):331-338
[DOI] 10.1016/j.cptl.2019.12.013.
[PMID] 32273072.
2020
Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
77(3):188-195
[DOI] 10.1093/ajhp/zxz307.
[PMID] 31974557.
2020
Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Clinical therapeutics.
42(9):e161-e176
[DOI] 10.1016/j.clinthera.2020.06.022.
[PMID] 32768247.
2020
Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic.
Journal of clinical medicine.
9(7)
[DOI] 10.3390/jcm9072274.
[PMID] 32708920.
2020
Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially Insured in the United States.
American journal of hypertension.
33(11):999-1002
[DOI] 10.1093/ajh/hpaa120.
[PMID] 32930343.
2020
Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008-2017.
International Journal of Cardiology. Hypertension.
6
[DOI] 10.1016/j.ijchy.2020.100033.
[PMID] 33447762.
2019
A stepwise approach to implementing pharmacogenetic testing in the primary care setting.
Pharmacogenomics.
20(15):1103-1112
[DOI] 10.2217/pgs-2019-0053.
[PMID] 31588877.
2019
Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
Therapeutic advances in drug safety.
10
[DOI] 10.1177/2042098619888133.
[PMID] 31807265.
2019
Antibiotic Stewardship for Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
American journal of therapeutics.
26(4):e499-e501
[DOI] 10.1097/MJT.0000000000000717.
[PMID] 29561269.
2019
Can apixaban prevent venous thromboembolism better than rivaroxaban? – Authors’ reply.
The Lancet. Haematology.
6(4):e181-e182
[DOI] 10.1016/S2352-3026(19)30049-3.
[PMID] 30926080.
2019
Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis.
Pharmacotherapy.
39(9):912-920
[DOI] 10.1002/phar.2311.
[PMID] 31332815.
2019
Comparison of Factors Identified by Patients and Physicians Associated with Hospital Readmission (COMPARE2).
Southern medical journal.
112(4):244-250
[DOI] 10.14423/SMJ.0000000000000959.
[PMID] 30943545.
2019
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
Lancet Haematology.
E20-E28
[DOI] 10.1016/52352-3026(18)30191-1.
2019
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
The Lancet. Haematology.
6(1):e20-e28
[DOI] 10.1016/S2352-3026(18)30191-1.
[PMID] 30558988.
2019
Effects of Oral Ginger Supplementation on the INR.
Case reports in medicine.
2019
[DOI] 10.1155/2019/8784029.
[PMID] 31281366.
2019
Patient-level adherence and interventions in an interdisciplinary DOAC clinic.
Thrombosis research.
179:34-36
[DOI] 10.1016/j.thromres.2019.04.021.
[PMID] 31075700.
2019
Risk of Daptomycin-associated Myopathy With Concomitant Statin Use.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
69(3):558-559
[DOI] 10.1093/cid/ciy1097.
[PMID] 30596967.
2018
Antibiotic use in patients hospitalized with chronic obstructive pulmonary disease.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
75(17):1268-1269
[DOI] 10.2146/ajhp180178.
[PMID] 30139734.
2018
Evaluation of SAMe-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring.
The Annals of pharmacotherapy.
52(11):1085-1090
[DOI] 10.1177/1060028018779774.
[PMID] 29857777.
2018
Incident-to Billing for Pharmacists.
Journal of managed care & specialty pharmacy.
24(12):1273-1276
[DOI] 10.18553/jmcp.2018.24.12.1273.
[PMID] 30479200.
2017
Resistant Hypertension: Mechanisms and Treatment.
Current hypertension reports.
19(7)
[DOI] 10.1007/s11906-017-0754-x.
[PMID] 28597403.
2016
Addressing Hospital Readmissions: Impact of Weekly Review.
Family medicine.
48(8):638-41
[PMID] 27655198.
2016
Patient satisfaction with extended-interval warfarin monitoring.
Journal of thrombosis and thrombolysis.
42(4):486-93
[DOI] 10.1007/s11239-016-1385-9.
[PMID] 27251646.
2016
Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.
Journal of the American Society of Hypertension : JASH.
10(4):307-17
[DOI] 10.1016/j.jash.2016.01.010.
[PMID] 26852290.
2015
Diagnosing and treating neurogenic orthostatic hypotension in primary care.
Postgraduate medicine.
127(7):702-15
[DOI] 10.1080/00325481.2015.1050340.
[PMID] 26012731.
2015
Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
72(19):1623-9
[DOI] 10.2146/ajhp140804.
[PMID] 26386103.
2015
Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.
Cardiovascular therapeutics.
33(3):98-103
[DOI] 10.1111/1755-5922.12115.
[PMID] 25786578.
2014
A Statin a Day to Keep the Doctor Away? Comparing Aspirin and Statins for Primary Prevention of Cardiovascular Disease.
The Annals of pharmacotherapy.
48(9):1238-1241
[PMID] 24958491.
2014
Davis and Dietrich’s response to Abramson and colleagues’ article on statins in low risk people.
BMJ (Clinical research ed.).
348
[DOI] 10.1136/bmj.g1795.
[PMID] 24574491.
2014
Feasibility of Extended Duration Follow-Up for Patients Receiving Warfarin.
Pharmacotherapy.
34(10)
2013
Canagliflozin: a novel treatment option for type 2 diabetes.
Drug design, development and therapy.
7:1399-408
[DOI] 10.2147/DDDT.S48937.
[PMID] 24285921.
2013
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Authors’ reply.
The Annals of pharmacotherapy.
47(3)
[PMID] 23463745.
2013
Lorcaserin for weight management.
Diabetes, metabolic syndrome and obesity : targets and therapy.
6:209-16
[DOI] 10.2147/DMSO.S36276.
[PMID] 23788837.
2013
New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Clinical therapeutics.
35(1):A3-17
[DOI] 10.1016/j.clinthera.2012.12.012.
[PMID] 23328274.
2013
Tracking Thrombosis and Pain Metrics in a Status- Post Orthopedic Surgical Population: Results From a Participating Institution in the Surgical Outcomes Project.
Pharmacotherapy.
33:E227-E228
2012
Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
The Annals of pharmacotherapy.
46(10):1382-91
[DOI] 10.1345/aph.1R069.
[PMID] 23012382.
Grants
Oct 2019
– Dec 2021
Quality of care for inferior vena cava filters at UF Health Shands Hospital
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Mar 2017
– Mar 2019
Pharmacogenetic Consultation Service
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Education
Certified Evaluation and Management Coder (CEMC)
2018
·
American Academy of Professional Coders
Certified Profession Coder (CDC),
2016
·
American Academy of Professional Coders
Post-doctoral fellow, Family Medicine
2011-2013
·
University of Florida
Pharm. D.
2011
·
University of Florida
Contact Details
Phones:
- Business:
- (352) 294-5648
Emails:
- Business:
- dietrich@cop.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
1707 N MAIN ST
GAINESVILLE FL 32609